Viridian Therapeutics Q3 2026 earnings

VRDN · 2026-11-04 07:11 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue from Lumvoa launch begins, but losses widen as SG&A increases and R&D remains high.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 94.1% (prior 0%, change +94.1 pp)
  • Operating expenses $129.2M (+16.9% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate 0% (prior-year 0%, year-to-date 0%)
  • Non-GAAP bridge No reconciliation provided.

KPIs

MetricActualPrior quarterPrior yearChange
Lumvoa net product revenue$24.7M$0$0+$24.7M
Patients on therapy100+00100+

Guidance

not stated in the 8-K

What drove it

  • Revenue story Product revenue of $24.7M from Lumvoa launch; total revenues of $25.8M, down 63.4% YoY due to a 64% drop in license revenue.
  • EPS story Loss per share widened to -$0.81 due to higher operating expenses and a larger share count.
  • One-off check None stated.

The good

  • Lumvoa net product revenue of $24.7M
  • 100+ patients on therapy

The bad

  • Net loss widened to $101.2M
  • SG&A increased to $57.6M (+136.7% YoY)
  • Cash balance declined to $955.2M

The ugly

  • none

Open questions

  • What caused the 136.7% YoY increase in Selling, General and Administrative expenses?
  • Why did License revenue drop from $70,000 to $125 in Q3 2026?
Full release

Viridian Therapeutics (VRDN) earnings release, November 4, 2026

Viridian Therapeutics, Inc. (VRDN) · Form 8-K, Item 2.02 · Filed · SEC filing

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

- $24.7 million in Lumvoa™

(veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -

- Elegrobart Biologics License Application (BLA) submission on track for Q1 2027 -

-

VRDN-008 phase 1 data disclosure on track for Q4 2026 -

-

VRDN-292, a potential best-in-class

TSHR inhibitor, expected to initiate a phase 1 clinical trial in patients in Q4 2026 -

- Cash, cash equivalents, and marketable securities of $955.2 million as of September 30, 2026 -

- Company to host webcast today, November 4, at 8:00 a.m. ET -

WALTHAM, Mass. – Nov. 4, 2026—Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30, 2026.

“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. “These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization. We are excited about this early momentum and look forward to building on it as we continue to execute our launch strategy and strive to bring Lumvoa to more patients with

TED. Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027. In addition, we look forward to several important milestones for the remainder of this year, including sharing clinical data for

VRDN-008, development plans for our FcRn portfolio, and initiating a first-in-human clinical trial in patients for our TSHR program

VRDN-292.”

Recent Business Highlights

THYROID EYE DISEASE

TSHR PROGRAM

FCRN PORTFOLIO

Financial Results

Conference Call and Webcast Information

Viridian will host a conference call and webcast today, November 4, at 8:00 a.m. ET to discuss third quarter 2026 financial results and recent business updates. The dial-in number for the conference call is +1

833-461-5787 for domestic participants and +1

585-542-9983 for international participants. The conference ID is 599668655.

A live webcast of the conference call can be accessed under “Events & Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. Following the live webcast, an archived version of the call will also be available on the Viridian website.

Upcoming Investor Conferences

Viridian will participate in the following upcoming investor conferences. Live webcasts of the presentations can be accessed under “Events & Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. Replays of the webcasts will be available following each event on the Viridian website.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.

With an immediate focus in thyroid eye disease (TED), we developed Lumvoa

TM, a full

IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on

LinkedIn and

X.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenues:
Product revenue, net24,671$—24,671$—
License revenue12570,00036470,000
Collaboration revenue - related parties9565701,142717
Total revenues25,75270,57026,17770,717
Operating expenses:
Cost of revenues1,5271,527
Research and development70,09386,261219,301249,721
Selling, general and administrative57,60924,322151,26361,642
Total operating expenses129,229110,583372,091311,363
Loss from operations-103,477-40,013-345,914-240,646
Total other income, net2,2685,41412,68518,400
Net loss-101,209-34,599-333,229-222,246
Net loss allocated to common stock-91,444-28,169-296,528-180,856
Net loss per share, basic and diluted, common stock-0.81-0.34-2.75-2.22
Weighted-average common shares outstanding, basic and diluted113,407,43281,784,499107,875,40881,576,987
Net loss allocated to Series A convertible preferred stock-7,160-3,097-24,605-19,934
Net loss per share, basic and diluted, Series A convertible preferred stock-53.76-22.96-183.26-147.81
Weighted-average Series A convertible preferred stock outstanding, basic and diluted133,191134,864134,263134,864
Net loss allocated to Series B convertible preferred stock-2,605-3,333-12,096-21,456
Net loss per share, basic and diluted, Series B convertible preferred stock-53.76-22.96-183.26-147.81
Weighted-average Series B convertible preferred stock outstanding, basic and diluted48,463145,16066,004145,160

Balance Sheet

September 30, 2026 — (Unaudited) (in thousands)

September 30, 2026December 31, 2025
Cash, cash equivalents, and marketable securities955,206874,652
Accounts receivable, net29,782
Other assets43,68224,766
Total assets1,028,670899,418
Total liabilities447,972177,251
Total stockholders’ equity580,698722,167
Total liabilities and stockholders’ equity1,028,670899,418

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (Unaudited)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-333,229-222,246
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense47,60632,314
Non-cash interest expense13,486308
Depreciation and amortization581340
Accretion and amortization of available-for-sale securities-4,864-5,005

This press release contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,”

“could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,”

“project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: that the company’s current commercial and medical affairs infrastructure will support an elegrobart launch; preclinical development, clinical development, and anticipated commercialization of Viridian’s product candidates, including the company’s intention to communicate development plan updates for Viridian’s FcRn portfolio in Q4 2026 and plans to initiate a phase 1 clinical trial for

VRDN-292 in Q4 2026; anticipated data results and timing of their disclosure, including

VRDN-008 phase 1 healthy volunteer data expected in Q4 2026; Viridian’s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including a BLA submission for elegrobart in the first quarter of 2027; elegrobart’s potential to be a subcutaneous therapy for the treatment of

TED with Q4W and Q8W dosing; Viridian’s product candidates potentially being best-in-class;

Viridian’s... (truncated)rket opportunities of veligrotug and elegrobart, if approved; and that Viridian’s cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart, will be sufficient to fund its business plans through profitability.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: that the company has historically incurred losses and may not be able to secure additional capital when needed; that the company has a limited history of generating revenue from product sales; that the company may be unable to maintain commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell veligrotug; market acceptance of veligrotug; potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of veligrotug and Viridian’s product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; the timing, progress and plans for ongoing or future research, preclinical, and clinical development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in Viridian’s clinical programs; the timing of and Viridian’s ability to obtain and maintain regulatory approvals for its therapeutic candidates; manufacturing risks; competition from other therapies or products; estimates of market size and market opportunity; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; Viridian’s financial position; Viridian’s future operating results and financial performance; Viridian’s intellectual property position; the timing of preclinical and clinical trial activities and reporting results from same; that Viridian’s product candidates may not be commercially successful, if approved; and other risks described from time to time in the “Risk Factors” section of our filings with the Securities and Exchange Commission, including those described in our most recent Annual Report on Form

10-K or Quarterly Report on Form

10-Q, as applicable, and supplemented from time to time by our Current Reports on Form

8-K.

Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof.

Viridian Therapeutics, Inc.

Condensed Consolidated Statements Of Operations

(In thousands, except share and per share data)

(Unaudited)

Viridian Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

Contacts

Investors

Greg Rossino grossino@viridiantherapeutics.com

Media

Lisa Lopez llopez@viridiantherapeutics.com

Source: Viridian Therapeutics,

Inc.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.